Arkuda Therapeutics is advancing novel targeted medicines for the treatment of frontotemporal dementia.
Location: United States, Massachusetts, Watertown
Total raised: $108M
Investors 3
| Date | Name | Website |
| - | Mission Bi... | missionbio... |
| - | Atlas Vent... | atlasventu... |
| 05.11.2022 | NFLS - Piv... | pivotalbio... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.02.2022 | Series B | $64M | - |
| 08.11.2019 | Series A | $44M | - |
Mentions in press and media 11
| Date | Title | Description |
| 15.02.2022 | Arkuda Therapeutics Raises $64M in Series B Financing | Arkuda Therapeutics, a Watertown MA-based biotechnology company, raised $64M in Series B funding. The round was led by Cormorant Asset Management and Pivotal bioVenture Partners, with participation from Surveyor Capital, Eli Lilly and Compa... |
| 10.02.2022 | Arkuda Therapeutics Raises $64 Million Series B Financing to Advance Pipeline of Programs Targeting Lysosomal Biology to Treat Neurodegenerative Diseases | WATERTOWN, Mass., Feb. 10, 2022 /PRNewswire/ -- Arkuda Therapeutics, a biotechnology company applying novel insights at the intersection of lysosomal and microglial biology to develop medicines to change the trajectory of neurodegenerative ... |
| 10.02.2022 | Arkuda Therapeutics Receives $64M Series B | WATERTOWN, MA, Arkuda Therapeutics today announced the completion of a $64 million Series B financing. >> Click here for more funding data on Arkuda Therapeutics >> To export Arkuda Therapeutics funding data to PDF and Excel... |
| 10.02.2022 | Neuro-focused Arkuda raises $64M as dementia drug moves closer to the clinic | Neurodegenerative disease drug developer Arkuda Therapeutics aims to treat brain diseases by addressing a component of cells that’s key to keeping neurons healthy. The preclinical biotech is making steady progress with its lead program, and... |
| 24.04.2020 | Laura Shawver on why she came back after an $88M windfall; MorphoSys taps Amgen vet as CCO | Laura Shawver Laura Shawver didn’t quite understand cancer until she had it. By that point, in 2006, she had already been making oncology drugs for over 15 years, a dyed-in-the-wool researcher who had obtained a PhD in pharma... |
| 08.11.2019 | Arkuda Therapeutics Inks $44M Series A | CAMBRIDGE, MA, Arkuda Therapeutics announced the completion of a $44 million Series A financing. >> Click here for more funding data on Arkuda Therapeutics >> To export Arkuda Therapeutics funding data to PDF and Excel, clic... |
| 08.11.2019 | Arkuda Therapeutics Raises $44M in Series A Financing | Arkuda Therapeutics, a Cambridge, Mass.-based company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease, completed a $44m Series A financing. The round ... |
| 07.11.2019 | Arkuda Therapeutics Closes $44M Series A | Arkuda Therapeutics, a company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease, today announced the completion of a $44 million Series A financing. Le... |
| 07.11.2019 | Arkuda bags $44M to target progranulin and head off inherited dementia | It’s a common refrain in dementia studies: “We should have treated them earlier.” It’s why treating neurodegenerative diseases has been so difficult, Gerhard Koenig, Ph.D., told FierceBiotech. “We believe that the challenges in treating neu... |
| 07.11.2019 | Arkuda bags $44M to target progranulin and head off inherited dementia | It’s a common refrain in dementia studies: “We should have treated them earlier.” It’s why treating neurodegenerative diseases has been so difficult, Gerhard Koenig, Ph.D., told FierceBiotech. Sponsored by Agilent Technologies How would you... |
Show more